

NovAliX Conference 2013

Biophysics in Drug Discovery

Programme

Tuesday October 15, 2013

Registration

Social Programme

Welcome Address

Chair

Dr Takaaki MIURA
(CHUGAI PHARMACEUTICAL, Kanagawa, Japan)

KN01 - Biophysical Methods and Fragment Based Drug Discovery: Targeting Protein-Protein Interactions in Cell Regulatory Systems

Prof. Sir Tom BLUNDELL
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

Welcome Reception

NovAliX Conference 2013

Biophysics in Drug Discovery

Programme

Wednesday October 16, 2013

Registration

1st Session - Biophysical Characterisation

Chair

Dr Johannes OTTL
(NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland)

PL01 - Binding of Drug Substances to Molecular Targets Investigated by Biophysical Methods

Dr Michael HENNIG
(F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland)

PL02 - Enabling GPCR Drug Discovery Through Structural and Biophysical Insights

Dr Rob COOKE
(HEPTARES, Hertfordshire, United Kingdom)

Coffee Break

OC01 - Biophysical Investigations of the Synergistic Activities of Antimicrobial Peptides: New Strategies to Fight Multiresistance

Prof. Burkhard BECHINGER
(UNIVERSITY OF STRASBOURG, Strasbourg, France)

OC02 - X-Ray Crystallography, Kinetic Target-Guided Synthesis and NMR to Unravel the Mode of Action of Insulin Degrading Enzyme Modulators

Prof. Rebecca DEPREZ-POULAIN
(UNIVERSITY OF LILLE, Lille, France)

PL03 - Biophysics to Drive Lead Discovery

Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

Lunch and Networking

2nd Session - Mechanistic Analysis

Chair

Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

PL04 - Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics: DOT1L and EPZ-5676

Dr Ann BORIACK-SJODIN
(EPIZYME, Cambridge, United States)

PL05 - Investing in Knowledge: Combining Biophysical Data in Fragment-Based Drug Discovery

Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

NovAliX Conference 2013

Biophysics in Drug Discovery

Programme

OC03 - Residence and Recognition Time and their Use for Structure Kinetic Relationships and for Judging Efficacy of Lead Series

Dr Markku HÄMÄLÄINEN
(GE HEALTHCARE BIO-SCIENCES, Uppsala, Sweden)

OC04 - Pharmacokinetics and the Drug-Target Residence Time Concept

Dr Göran DAHL
(ASTRAZENECA, Mölndal, Sweden)

Coffee Break

OC05 - Bringing Light into Antibody Binding Characteristics in Crude Extracts by Means of FCCS

Dr Frank BECKER
(INTANA BIOSCIENCE GMBH, Planegg, Germany)

PL06 - Can we Use Kinetics and Thermodynamics to Guide Drug Discovery?

Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom)

Chair

Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom)

KN02 - Molecular Mechanism of Action (MMOA) in Drug Discovery

Dr David SWINNEY
(IRND3, Mountain View, United States)

Entertainment (optional & subject to prior registration)

NovAliX Conference 2013

Biophysics in Drug Discovery

Programme

Thursday October 17, 2013

3rd Session - Emerging Technologies

Chair

Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

PL07 - Label-Free, Immobilisation-Free Interaction Studies Using Microscale Thermophoresis

Dr Stefan DUHR
(NANOTEMPER, Munich, Germany)

PL08 - Backscattering Interferometry: An Enabling Drug Development Technology

Dr Darryl BORNHOP
(VANDERBILT UNIVERSITY, Nashville, United States)

OC06 - Detection and Analysis of Proteins with an Electro-Switchable DNA Chip

Dr Ralf STRASSER
(DYNAMIC BIOSENSORS GMBH, Martinsried, Germany)

Coffee Break

OC07 - Binding Rate Constants Measured on Microliter Volume Using On-Chip Temperature Modulation and Fluorescence Lock-In Detection

Dr Charlie GOSSE
(CNRS, Marcoussis, France)

OC08 - CRYO-TEM: The Way to Answer Real Biological Questions through Unraveling the 3D Mechanistics of Protein

Dr Thomas WOHLFARTH
(FEI, Eindhoven/Acht, The Netherlands)

PL09 - Towards Personalised Cancer Medicine with New NMR Tools to Probe Small GTPase Proteins

Dr Chris MARSHALL
(UNIVERSITY OF TORONTO, Toronto, Canada)

Lunch and Networking

Poster Session

Coffee Break

Round-table discussion on hot topics, emerging trends, and new techniques & approaches; sharing of experience and questions from the audience to a panel of experts

Moderator

Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Poster Prizes

NovAliX Conference 2013

Biophysics in Drug Discovery

Programme

Chair

Dr Michael HENNIG
(F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland)

KN03 - Combining X-Ray Crystallography and Single-Molecule Methods to Probe Antibiotic Inhibition of Translation

Prof. Jamie CATE
(UNIVERSITY OF CALIFORNIA, Berkeley, United States)

Conference Dinner (optional & subject to prior registration)

NovAliX Conference 2013

Biophysics in Drug Discovery

Programme

Friday October 18, 2013

4th Session - Biophysical Methods for Identifying Hits and Leads

Chair

Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)

PL10 - Application of SPR Biosensors Throughout the Drug Discovery Process

Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

PL11 - Finding Active Ligands to kRAS Using Solution State NMR

Dr Till MAURER
(GENENTECH, South San Francisco, United States)

Coffee Break

OC09 - Identification and Validation of Small Molecule Inhibitors of G Protein Beta 1 Gamma 2

Dr Preeti BAKRANIA
(MRC TECHNOLOGY, London, United Kingdom)

OC10 - Fragments at UCB: Implementation of Non-Covalent Mass Spectrometry and ¹⁹F NMR as Orthogonal Screening Techniques

Dr Hannah MAPLE
(UCB, Slough, United Kingdom)

PL12 - Biophysics in Pharmaceutical Lead Discovery

Dr Johannes OTTL
(NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland)

Closing Remarks and Departure